<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427374</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000387</org_study_id>
    <secondary_id>IRO 90262</secondary_id>
    <nct_id>NCT01427374</nct_id>
  </id_info>
  <brief_title>Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients</brief_title>
  <official_title>Clinical, Biochemical and Genetic Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients (CKDCS/LUCID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals with kidney disease are at a higher risk for heart and vascular diseases,&#xD;
      including heart attacks and strokes, than those with normal kidney function. The purpose of&#xD;
      this research study is to collect information on the causes, complications and treatment of&#xD;
      kidney disease. Patient characteristics, comorbid diseases and laboratory markers used in&#xD;
      routine practice, as well as novel biochemical markers and genetic data will be collected to&#xD;
      examine relationships between biochemical and genetic markers and cardiovascular risk.&#xD;
      Information on the health history of incident hemodialysis and peritoneal dialysis patients&#xD;
      will be captured using structured patient interviews and review of medical records. Blood and&#xD;
      urine specimens will be collected at the time of dialysis initiation and stored in order to&#xD;
      perform novel biochemical and genetic assays in the future. The overall goal of the&#xD;
      CKDCS/LUCID study is improve understanding of cardiac-associated risks and to improve&#xD;
      treatment in patients with kidney disease. A cardiac imaging substudy will be performed in a&#xD;
      subset of patients enrolled. The goals of the substudy are to examine whether the risks of&#xD;
      developing common cardiac-related complications (coronary artery calcification [CAC] and left&#xD;
      ventricular hypertrophy [LVH]) are associated with certain medications taken by individuals&#xD;
      on dialysis and whether these risks are modified by a genotypic predisposition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted under the Sponsorship of the University of Alberta (Edmonton,&#xD;
      Alberta, Canada) and is funded by Canadian Institutes of Health Industry Partnered Research&#xD;
      Grant IRO 90262 - with partnership funding from Abbott Laboratories. The co-Principal&#xD;
      Investigators are Marcello Tonelli MD SM and Ravi Thadhani, MD, MPH . A total of 750 patients&#xD;
      are anticipated being enrolled at Massachusetts General Hospital (MGH). The remaining&#xD;
      patients are being enrolled in Canada.&#xD;
&#xD;
      This study will utilize data from &quot;The Canadian Kidney Disease Cohort Study&quot; (CKDCS) and &quot;The&#xD;
      Longitudinal US/Canada Incident Dialysis STUDY (LUCID).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">May 2011</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Artery Calcification</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary Artery Calcification</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular hypertrophy</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>End Stage Renal Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine will be obtained at baseline, 6 months and annually thereafter. Blood samples&#xD;
      will be immediately divided into multiple aliquots, from which plasma, DNA, RNA and/or cells&#xD;
      will be extracted and separately stored. Urine specimens will also be aliquoted to allow&#xD;
      future measurement of genetic and cellular material. Specimens will be labeled using unique&#xD;
      study identifiers to maintain confidentiality.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Incident hemodialysis and peritoneal dialysis patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (≥ 18 years of age) commencing hemodialysis or peritoneal dialysis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Unable to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria for the cardiac substudy:&#xD;
&#xD;
        CT exclusion criteria&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Obesity (&gt;275 lbs)&#xD;
&#xD;
          3. Rapid atrial fibrillation, bigeminy or trigeminy&#xD;
&#xD;
          4. Any condition that impedes the ability to lie flat during the CT (eg:decompensated&#xD;
             congestive heart failure).&#xD;
&#xD;
        MRI exclusion criteria&#xD;
&#xD;
          1. Cardiac pacemaker or implantable defibrillator&#xD;
&#xD;
          2. Obesity (&gt;275lbs)&#xD;
&#xD;
          3. Intraocular metal&#xD;
&#xD;
          4. Cerebral aneurysm clips, programmable shunt, etc.&#xD;
&#xD;
          5. Any type of ear implant&#xD;
&#xD;
          6. Any implanted device (eg: insulin, drug infusion device)&#xD;
&#xD;
          7. Metal shrapnel or bullet&#xD;
&#xD;
          8. Any condition that impedes the ability to lie flat during the MRI (eg:decompensated&#xD;
             congestive heart failure)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Thadhani, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcello Tonelli, MD, SM, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195U</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2011</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Marcello Tonelli</investigator_full_name>
    <investigator_title>MD, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>peritoneal dialysis</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>cardiovascular risk factors</keyword>
  <keyword>cardiac imaging</keyword>
  <keyword>dialysis</keyword>
  <keyword>parathyroid hormone</keyword>
  <keyword>vitamin D</keyword>
  <keyword>coronary artery calcification</keyword>
  <keyword>left ventricular hypertrophy</keyword>
  <keyword>genetic predisposition</keyword>
  <keyword>biochemical markers</keyword>
  <keyword>infection</keyword>
  <keyword>pharmacogenomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

